Supplementation of Standard Antibiotic Therapy With Oral Probiotics for Bacterial Vaginosis

Bacterial Vaginosis Clinical Trial

Official title:

Efficacy and Safety Assessment of prOVag Dietary Supplement in Recurrent Bacterial Vaginitis. Multi-centre, Randomized, Double-blind, Placebo-controlled Clinical Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01993524
• Other study ID #: PB-DM/SBK-prOVag2-01/08
• Status: Completed
• Phase: N/A
• First received: October 29, 2013
• Last updated: November 20, 2013
• Start date: March 2009
• Est. completion date: February 2012

Study information

• Verified date: November 2013
• Source: IBSS Biomed S.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Poland: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to determine whether supplementation of standard antibiotic therapy with oral probiotic preparation prOVag containing lactic acid bacteria influences recurrence of bacterial vaginosis/vaginitis.

Description:

Bacterial vaginosis is the most common vaginal infection in women of reproductive age. This condition is caused by an overgrowth of anaerobic bacteria with concomitant reductions in Lactobacillus populations in the vagina, i.e. disruption of the vaginal microbiota. Aerobic vaginitis is related to the suppression of lactobacilli by various aerobic bacteria, mostly originating from the anal microbiota.

Previous open-label study confirmed that probiotic strains - Lactobacillus fermentum 57A, Lactobacillus plantarum 57B, and Lactobacillus gasseri 57C given orally to women with intermediate/abnormal vaginal flora and no clinical symptoms had the ability to colonize rectum and vagina and contributed to the maintenance of pH level and Nugent score. The colonisation of women with tested strains had been confirmed by microbiological and molecular methods.

The purpose of this multicentre, randomized study was to investigate whether the use of a probiotic preparation containing Lactobacillus fermentum 57A, Lactobacillus plantarum 57B, and Lactobacillus gasseri 57C together with standard treatment for bacterial vaginosis/vaginitis could reduce the recurrence rates of these conditions, as assessed using clinical and microbiological criteria, in comparison with standard treatment alone. The study took place between March 2009 and February 2012 in nine private out-patient gynaecological clinics in the Krakow area and Katowice (Silesia) in Poland. It was conducted in accordance with the original protocol and according to ICH-GCP requirements. The duration of subject's participation in the trial was approximately 5-6 months (follow-up visit included). As the trial did not concern medicinal product but the foodstuff (dietary supplement) it did not require Authority approval but was only subject to relevant Ethics Committee approval.

Women with history of recurrent bacterial vaginosis/vaginitis, aged 18 - 50 years, who complied with inclusion and exclusion criteria and who signed informed consent form were enrolled and randomized into one of the study groups.

Efficacy parameters were based on the evaluation of clinical symptoms during gynaecological examinations, as well as the determination of vaginal pH, Nugent score, total Lactobacillus counts and presence/numbers of vaginal pathogens in cultures from vaginal swabs collected at each visit. Data obtained at the third-fifth visits were compared with those obtained at the first visit. Clinical samples were transported to central laboratory for further analysis.

Safety parameters were analysed using information recorded in 'patient's diaries' throughout the study period, as well as the investigator's assessments at each visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 594
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Informed Consent Form

2. Subjects aged more than or equal 18 and less than or equal 50 years

3. Women of the Caucasian race

4. Regularly menstruating premenopausal women (normal menstrual function (Eumenorrhoea) shall mean regular menstrual bleeding pattern every 28 plus/minus 10 days)

5. No irregularities identified in gynaecological examination (no pathology of reproductive organs, such as myomas, ovarian cysts)

6. Susceptibility to recurrent vaginitis and/or urinary tract infections, as well as bacterial vaginitis confirmed at visit I

Exclusion Criteria:

1. Subjects aged less than 18 and more than 50 years

2. Hypersensitivity to any ingredient of the investigational product, metronidazole or antibiotic(s).

3. Bleeding from genital tract of unknown aetiology

4. Pregnancy

5. Breastfeeding

6. Congenital and acquired immunodeficiencies

7. Diabetes

8. Mental illness

9. Neoplastic disease

10. Application of mechanical contraceptives, such as: diaphragms, intrauterine contraceptive insert (except for Mirena intrauterine device)

11. Application of NuvaRing hormonal contraceptive vaginal ring

12. Application of hormonal preparations, such as: Vagifem, Ovestin and vaginal estrogens in reproductive period

13. Application of another oral and/or vaginal probiotic at Subject qualification to the Study

14. Participation in another clinical study / less than thirty-day interval from the last clinical study

15. Mycotic vaginitis

16. Antibiotic therapy for other reasons

17. Pathology of reproductive organs (myomas, ovarian cysts, etc.)

18. Scheduled surgery or hospitalization

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Bacterial Vaginitis
• Bacterial Vaginosis
• Vaginal Diseases
• Vaginitis
• Vaginosis, Bacterial

Intervention

Dietary Supplement:
• probiotic
antibiotic plus probiotic

Other:
• placebo
antibiotic plus placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
IBSS Biomed S.A.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduced probability of recurrent bacterial vaginosis/vaginitis.	Recurrence of bacterial vaginosis/vaginitis at the third-fifth visits was considered to be the study endpoint (participant's withdrawal). The reduced probability of recurrent bacterial vaginal infection, confirmed by clinical and/or microbiological symptoms, was the parameter used to assess primary efficacy.	assesed on visits III-V (assesed monthly within three months)	Yes
Secondary	Change in vaginal pH level.	Determination of pH level of vaginal discharge using indicator paper at each visit, comparison of the test outcome with the test result at Visit I.	assesed monthly within five-six months	Yes
Secondary	Change in Nugent score level.	Assessment according to the Nugent score at each visit; comparison of the outcomes with the assessment at Visit I.	assesed monthly within five-six months	Yes
Secondary	Change in total Lactobacillus counts a in cultures from vaginal swabs.	Total count of Lactobacillus bacteria in vaginal flora in material collected at each visit.Data obtained at the third-fifth visits were compared with those obtained at the first visit.	assesed monthly within five-six months	Yes
Secondary	The time to bacterial vaginosis/vaginitis recurrence	The time to bacterial vaginosis/vaginitis recurrence was measured from the visit on which a participant showed no symptoms: the second visit for participants on standard metronidazole treatment and the second visit bis for participants treated with metronidazole and targeted antibiotics.	assesed on visits III-V (assesed monthly within three months)	Yes